Market Research Logo

Healthcare Market Research Reports & Industry Analysis

These reports detail the ever-changing world of healthcare and all of its nuances and sub-categories. Healthcare cannot be narrowly defined nor can one report detail what is happening around the globe. provides detailed reports for various countries around the world and the healthcare needs and offerings in those countries. These reports also profile the types of administrations and regulations and policies that are in place in various regions and segments in each country.

Reports are available in industry sub-categories such as: wellness and preventative programming, sports medicine, insurance and managed care, and clinical guidelines and best practices. Readers may also find data regarding alternative and complementary medicine, nursing, public health and information technology. Though not always considered when first thinking of healthcare, information may also be found on veterinary health.

Reviews of various equipment and pharmaceuticals in specific regions are made available regarding multiple countries. Herbal and traditional products are contrasted and compared, and global access to sufficient ambulance services is discussed.

...Show More ...Show Less

Healthcare Industry Research & Market Reports

  • Ambulatory Health Care Services

    ... companies include Apria Healthcare, DaVita, and LabCorp (all based in the US), as well as Bayshore HealthCare (Canada), Fresenius (Germany), and Sonic Healthcare (Australia). COMPETITIVE LANDSCAPE Pressure on the health care industry to drive down ... Read More

  • Physicians

    ... costs while improving quality of care. The profitability of individual practices depends on the reputation, cost, operational efficiencies, and expertise of the physician and staff. Large practices have advantages in leveraging administrative processes and expensive ... Read More

  • Pediatricians

    ... by demographics. The profitability of pediatrics practices depends on efficient operations and health care reimbursement rates. Large practices may be able to leverage the costs of administrative staff and equipment. Small or solo practices may ... Read More

  • Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

    ... filters) that prevent occurrence of nosocomial infections. Within each type of treatment, regional analyses will focus on the Americas (i.e. Canada, the U.S., Mexico, Central America and South America), EMRA (i.e. Europe, the Middle East, ... Read More

  • Indonesia Pharmaceuticals & Healthcare Q4 2018

    ... health insurance scheme (JKN), further expansion will be hampered by deficit,investment shortages and uneven levels of healthcare access across the country. Additionally, for the pharmaceutical industry, theJKN's positive impact on growth is likely to wane ... Read More

  • Morocco Pharmaceuticals & Healthcare Q4 2018

    ... treatments. Although the government'scommitment to improving healthcare via the expansion of health insurance coverage will be a significant factor for future medicinesales growth, we believe generics drugmakers will be the main beneficiaries as the state ... Read More

  • Mutuelle Generale de l'Education Nationale - Strategic SWOT Analysis Review

    ... the company’s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors ... Read More

  • Colombia Pharmaceuticals & Healthcare Q4 2018

    ... Colombia. However, despite price control measures and a weak intellectual property environment, healthcarereforms and the rising burden of chronic diseases will facilitate the rising demand for medicines – boosting the consumption ofmedicines in volume terms. Read More

  • Kyrgyzstan Pharmaceuticals & Healthcare Q4 2018

    ... Kyrgyzstan's small and highly ruralised population will continue to restrict opportunities for multinational pharmaceuticalfirms. Key barriers for access to modern medicines include a lack of spending power and challenges in supply and distributionacross the country. Read More

  • Spain Pharmaceuticals & Healthcare Q4 2018

    ... of the generic drug sector and the government’s continuedfocus on cost-containment measures targeting prescription drug expenditure. These trends, along with a subdued economicoutlook, make Spain one of the more challenging markets in Western Europe for ... Read More

  • Canada Pharmaceuticals & Healthcare Q4 2018

    ... environment maintains Canada's attractiveness for drugmakers,including opportunities to establish manufacturing facilities. However, drugmakers will be challenged by the increasing use ofaggressive pricing policies, with historically high generics prices increasingly becoming a target for cost-containment measures. Read More

  • Puerto Rico Pharmaceuticals & Healthcare Q4 2018

    ... targeting drug spending rise and the US administration maintainsa stringent stance towards securing federal healthcare funds for Puerto Rico. Economic challenges and outward migration of labourwill further raise risks to the island's attractiveness to manufacturers, ... Read More

  • Tanzania Pharmaceuticals & Healthcare Q4 2018

    ... limited by low per capita spending on medicines andan underdeveloped healthcare sector. Whilst demand for medicine will increase over the long-term, driven by the country’s rapidlyexpanding population and high disease burden, we expect that Tanzania's ... Read More

  • Premier Inc (PINC) - Financial and Strategic SWOT Analysis Review

    ... you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand ... Read More

  • Philippines Pharmaceuticals & Healthcare Q4 2018

    ... prominent theme within the Philippines pharmaceutical market, repressing drugmakersales growth. With the expansion of universal health coverage, these pressures will increase, offsetting the positive impact ofincreased access to services and a reduction in out-of-pocket payments. Read More

  • Russia Pharmaceuticals & Healthcare Q4 2018

    ... policy continuity will lead toincreased investment in localised drug production in the market, although this will remain heavily weighted towards the genericmedicines sector given the continued regulatory issues and market access barriers for innovative drugmakers. Read More

  • Iran Pharmaceuticals & Healthcare Q4 2018

    ... and has triggered intense negotiations surrounding theIslamic Republic's future ability to integrate into the global economy. Although the supply of medical equipment and devices willsteadily decline, Iran's healthily domestic drug production capabilities and limited exposure ... Read More

  • Estonia Pharmaceuticals & Healthcare Q4 2018

    ... patients with high drug costs. Over the long-term,patented medicine sales will be supported by an ageing demographic and the high prevalence of cardiovascular disease andcancers. However, multinational drugmakers’ interest in the market will remain limited ... Read More

  • Ethiopia Pharmaceuticals & Healthcare Q4 2018

    ... government is strongly committed to improvingthe operating environment to attract foreign investment, particularly from China, which combined with a budding manufacturingsector bodes well for foreign drugmaker appetite. Over the near-term, multinational drugmaker investment in the ... Read More

  • Laos Pharmaceuticals & Healthcare Q4 2018

    ... improving the population’s access to healthcare, the still underdevelopedhealth system will limit drugmaker opportunities. While the rising burden of communicable diseases and the gradual rolling-out ofuniversal healthcare will present improved commercial opportunities for drugmakers over ... Read More

  • Peru Pharmaceuticals & Healthcare Q4 2018

    ... to medicine, butwith limited resources available to the government, cost containment measures will pose challenges to innovative drugmakers.However, the improved but hostile political environment, following the resignation of the formal president poses upside risks toinvestment. Read More

  • Bahrain Pharmaceuticals & Healthcare Q4 2018

    ... preference of branded medicine over generic drugs. Furthermore, thegradual improvement of intellectual property protection and regulatory enforcement coupled with the establishment of acompulsory national health insurance scheme will provide greater investment opportunities for multinational drugmakers ... Read More

  • Saudi Arabia Pharmaceuticals & Healthcare Q4 2018

    ... 2030’ encouraging the expansion of manufacturingagreements in the country. While regulatory risks remain prevalent, and recent disputes with European players highlightchallenges of doing business in the country, positive market drivers will ensure robust long-term opportunities ... Read More

  • Highmark Inc - Strategic SWOT Analysis Review

    ... key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope Business description ... Read More

  • Parkway Pantai Ltd - Strategic SWOT Analysis Review

    ... employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope Business ... Read More

< prev 1 3 4 5 6 7 8 9 10